(Updates with Novartis statement throughout.)
Novartis (NVS) said Thursday it will close its MorphoSys sites in Germany and the United States by the end of 2025, impacting about 330 jobs.
The drugmaker said the decision is part of its strategic evaluation of its evolving research and development portfolio, focusing on prioritizing scientific expertise and resources for key programs.
It added that the closure is also influenced by the extended follow-up time required to determine the approval pathway for pelabresib, a treatment for myelofibrosis.
NVS shares were edging 0.6% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments